3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Non-Hodgkin
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Glioblastoma
1
Carcinoma, Squamous Cell
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
pembrolizumab
72
Cisplatin
57
Cetuximab
38
Fluorouracil
25
Nivolumab
21
Radiotherapy
20
Carboplatin
19
Paclitaxel
14
Docetaxel
11
Cyclophosphamide
9
Gefitinib
8
fludarabine
7
durvalumab
7
zalutumumab
6
atezolizumab
6
Drug Therapy
6
Bleomycin
6
epacadostat
5
cemiplimab
5
Radiotherapy, Intensity-Modulated
5
Pemetrexed
5
Ipilimumab
5
Gemcitabine
5
Afatinib
5
spartalizumab
4
Standard of Care
4
Radiation
4
Injections
4
Immune Checkpoint Inhibitors
4
Fibroblast Growth Factor 7
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Head and Neck Neoplasms
×
Proton Pump Inhibitors
×
Clear all
NCT02609386
2024-01-30
INSPIRE
Brooklyn ImmunoTherapeutics, LLC
Phase 2
Completed
105 enrolled
17 charts